<SEC-DOCUMENT>0000950170-25-066366.txt : 20250508
<SEC-HEADER>0000950170-25-066366.hdr.sgml : 20250508
<ACCEPTANCE-DATETIME>20250508070531
ACCESSION NUMBER:		0000950170-25-066366
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250508
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250508
DATE AS OF CHANGE:		20250508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Q32 Bio Inc.
		CENTRAL INDEX KEY:			0001661998
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				473468154
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38433
		FILM NUMBER:		25923815

	BUSINESS ADDRESS:	
		STREET 1:		830 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		781-999-0232

	MAIL ADDRESS:	
		STREET 1:		830 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Homology Medicines, Inc.
		DATE OF NAME CHANGE:	20151228
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>qttb-20250508.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-08T07:03:18.1613+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:qttb="http://www.q32bio.com/20250508">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_92c8ec95-21b0-4e9f-9462-38a1337cbf50" name="dei:AmendmentFlag" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4">false</ix:nonNumeric><ix:nonNumeric id="F_0398cdf9-7f98-495b-8b83-4adf1550d5fa" name="dei:EntityCentralIndexKey" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4">0001661998</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="qttb-20250508.xsd"/></ix:references><ix:resources><xbrli:context id="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-08</xbrli:startDate><xbrli:endDate>2025-05-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_684fbbcf-7770-401e-bd5f-f47e969627f3" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_e9f10ee6-5616-4c1c-ba34-c73c4923b7db" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">May 08, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42ee7a28-cb72-430a-84e6-f485a38aee62" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Q32 Bio Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_63fa0557-962d-47a7-ac7e-d774dc7ddf33" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f918bfd0-8853-43f1-95a2-0887a9078987" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-38433</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_78822aaa-02b7-433f-bd80-a116e3ea6095" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">47-3468154</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_bbb2cd4c-5bd9-46e4-a0e7-50bc4fddd119" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">830 Winter Street</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b157d42a-60b4-4a63-9ede-ef87e0ea5f2d" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Waltham</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_ba640e0c-935d-4c6a-891f-49108eb93144" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_aafc79f2-7bc2-42d2-bf78-d3c426ae2c8b" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02451</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_73615c3f-9473-41fd-81c8-1dc66481fc48" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">781</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_c2d82a18-11a5-4af0-92e7-7b0015a084ab" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">999-0232</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_acbe1bb1-28f3-41f7-bdab-d717c9c15826" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">N/A</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3bb62ecb-e4e9-43d4-90e0-2108e2436f85" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32b01bca-6709-4383-ab07-6a2d60826d47" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d483e4ef-28e5-473d-854b-9b3335a1d68b" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2765ec59-2632-4830-a760-41aa4e7e90eb" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e4a3d822-3ac0-4b8b-8663-ccfb8827d39a" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c74d65b2-afc5-4950-9d62-bf5dcd8b3117" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">QTTB</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2bfad280-b03e-4024-a148-4610b1f35cd9" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_bd2c5136-bad5-4976-89db-dce3b3a1e48f" contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></h2><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 8, 2025, Q32 Bio Inc. announced its financial results for the quarter ended March 31, 2025 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></h2>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:5.059%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:93.921%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="qttb-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release issued by Q32 Bio Inc. on May 8, 2025</span></a></p></td>
    </tr>
    <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:3.5pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:43%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Q32 BIO INC.</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 8, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jodie Morrison</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jodie Morrison<br/>Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>qttb-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-114.285%;padding-left:53.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p><p style="text-indent:-114.285%;padding-left:53.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-114.285%;padding-left:53.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img38152436_0.jpg" alt="img38152436_0.jpg" style="width:142px;height:32px;"></p><p style="text-indent:-114.285%;padding-left:53.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-114.285%;padding-left:53.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-114.285%;padding-left:53.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">-- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H&#x2019;26 --</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">-- First patient dosed in SIGNAL-AA Part A open label extension (OLE) --</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">-- Fast Track designation (FTD) granted to bempikibart for the treatment of alopecia areata (AA); SIGNAL-AA Part A results presented as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting --</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">-- Cash and cash equivalents of $65.5 million as of March 31, 2025 expected to provide financial runway into 2H&#x2019;26 --</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">WALTHAM, Mass.&#x2014;May 8, 2025</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> &#x2013; Q32 Bio Inc. (Nasdaq: QTTB) (&#x201c;Q32 Bio&#x201d;), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended March 31, 2025, and provided recent corporate updates.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;This past quarter brought exciting momentum for Q32 Bio and bempikibart as we received Fast Track designation, presented results as a late-breaking oral presentation at AAD, and advanced our SIGNAL-AA Phase 2a clinical trial, dosing the first patients in both Part B and the Part A OLE. These steps reflect our ongoing progress and commitment to developing bempikibart as a potential treatment for patients with alopecia areata who need new treatment options,&#x201d; said Jodie Morrison, Chief Executive Officer of Q32 Bio. &#x201c;We look forward to sharing topline data from Part B in the first half of next year and continuing our efforts to advance bempikibart.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">First Quarter 2025 and Recent Business Highlights</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">FTD granted to bempikibart for the treatment of AA.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Fast Track is a process designed to facilitate the development and expedite the review of new drugs to treat serious diseases and fill an unmet medical need with the purpose of getting important new drugs to patients earlier. Filling an unmet medical need is defined as providing a therapy where either none exists or providing a therapy which may be potentially better than available therapies. A drug that receives FTD may be eligible for more frequent meetings and communications with the FDA to discuss development plans and ensure the collection of appropriate data needed to support approval and for a rolling review of an application for marketing approval. Drugs receiving FTD may also be eligible for Accelerated Approval and Priority Review if relevant criteria are met.</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Dosed the first patient in Part B of the SIGNAL-AA Phase 2a clinical trial, with topline data readout on-track for the first half of 2026. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Part B of the SIGNAL-AA Phase 2a clinical trial is an open-label clinical trial evaluating bempikibart, a fully human anti-IL-7R&#x3b1; antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling, in patients with severe or very severe AA. The trial will dose approximately 20 evaluable patients with severe or very severe AA with bempikibart for 36 weeks, with follow-up out to 52 weeks. Dosing includes an initial loading regimen of 200mg of bempikibart dosed weekly over four weeks, followed by a maintenance dose of 200mg every-other-week over a 32-week period for a total dosing period of 36 weeks. Efficacy will be evaluated on the basis of mean percentage change from baseline in Severity of Alopecia Tool (SALT) scores as well as the proportion of subjects achieving various relative and absolute SALT improvements at week 36, with follow-up through week 52. The trial is intended to support advancement into pivotal trials upon completion, pending review of the results. Q32 Bio expects to report topline results in the first half of 2026.</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Dosed the first patient in Part A OLE of the SIGNAL-AA Phase 2a clinical trial. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Based on the continued emergence of bempikibart data suggesting a remittive effect and durable responses in long-term follow-up from SIGNAL-AA Part A, as well as re-consent rates and strong patient demand for continued dosing, Q32 Bio has initiated an OLE for eligible patients that completed Part A to enable longer-term follow up of patients. Patient enrollment and dosing is ongoing. </font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Presented results from SIGNAL-AA Phase 2a Part A clinical trial of bempikibart in AA as a late-breaking oral presentation at the AAD Annual Meeting. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The late-breaking presentation highlighted additional results from Part A of the SIGNAL-AA Phase 2a clinical trial of bempikibart beyond what was previously reported in the topline readout in December. In a difficult-to-treat severe and very severe patient population with an average duration of current episode greater than five years, bempikibart demonstrated clinically meaningful activity at week 24 and continued effects after dosing cessation. Despite only 24 weeks of bempikibart treatment, a deepening response, as measured by mean percent change in SALT compared with baseline, was observed following dosing cessation (week 24) through the post-treatment follow-up period (week 36), a paradigm believed to be associated with IL-7 on-mechanism modulation of rebalancing T effector memory cells and T regulatory function. Additional data has been collected on patients after week 36, with follow-up on multiple patients through week 55 to date, and additional long-term follow-up ongoing. Outreach was made to patients regarding the post-treatment experience and patients willing to participate were re-consented. Amongst patients responding to outreach that completed the treatment period and showed a SALT response during the trial (n=12), all achieved maintenance of response or further hair growth in the post treatment period (post 24 weeks), including after the end of the trial (post 36 weeks). All 12 were confirmed by SALT assessment by the investigator, with a median follow-up of 41 weeks to date (17 weeks post last treatment) with additional follow-up ongoing. Of these, seven patients (7/12) showed additional hair growth by SALT assessment post-treatment, with </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">median follow-up of 44 weeks to date (20 weeks post last treatment) with additional follow-up ongoing. Across clinical trials, including SIGNAL-AA, bempikibart was observed to be safe and well-tolerated, with no grade 3 or higher related adverse events or related viral infections. Robust pharmacologic activity through desired target engagement was observed, as demonstrated by receptor occupancy, robust changes in Th2 biomarkers, and expected on-mechanism changes in T-cells, indicative of potent IL-7 and TSLP inhibition. The full AAD presentation is available on the &#34;Presentations and Publications&#34; page of the Q32 Bio website.</font></div></div><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Financial Results</font></p><div class="item-list-element-wrapper" style="margin-left:2.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.237505514913352%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents were $65.5 million as of March 31, 2025. Q32 Bio believes its cash and cash equivalents are sufficient to fund operations into the second half of 2026, through the SIGNAL-AA OLE and topline results of the SIGNAL-AA Part B trial evaluating bempikibart in patients with AA.</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:2.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.237505514913352%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Research and development expenses were $7.1 million for the three months ended March 31, 2025, compared to $9.8 million for the three months ended March 31, 2024. The decrease in expense of $2.7 million was primarily due to higher clinical development expenses for bempikibart Phase 2 clinical trials in AA and atopic dermatitis in 2024.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:2.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.237505514913352%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative expenses were $5.1 million for the three months ended March 31, 2025, consistent with $5.0 million for the three months ended March 31, 2024. </font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:2.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.237505514913352%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net loss was $(11.0) million, or $(0.90) basic and diluted net loss per share, for the three months ended March 31, 2025, compared to net income of $1.0 million, or $1.03 basic and ($6.33) diluted net loss per share, for the three months ended March 31, 2024. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About Q32 Bio</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7R&#x3b1; antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">For more information, visit www.Q32Bio.com.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">National Alopecia Areata Foundation</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Availability of Other Information About Q32 Bio</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com, including, but not limited to, Q32 Bio&#x2019;s disclosures, investor presentations and FAQs, Securities and Exchange Commission (the &#34;SEC&#34;) filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Q32 Bio&#x2019;s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements contained herein which do not describe historical facts are forward-looking statements, including, among others, Q32 Bio's beliefs, observations, expectations and assumptions regarding the data reported to date from Part A of the SIGNAL-AA Phase 2a clinical trial, the plan, purpose and timing of Part B of the SIGNAL-AA Phase 2a clinical trial and the anticipated timing of its data, the safety, tolerability, clinical activity, durability, potential efficacy and potential benefits of bempikibart, the potential benefits conferred by FTD for bempikibart, and Q32 Bio&#x2019;s beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, including statements regarding the sufficiency of its cash and cash equivalents to provide financial runway through clinical milestones and into second half of 2026; which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Forward-looking statements are based on management's current beliefs and assumptions, which are subject to risks and uncertainties and are not guarantees of future performance. Such risks and uncertainties include, among others, the risk that additional data, or the results of ongoing data analyses, may not support Q32 Bio&#x2019;s current beliefs and expectations for bempikibart, including with respect to the durability of clinical responses, the risk that ongoing and future clinical studies, including Part B of the SIGNAL-AA Phase 2a clinical trial, may not be completed by the first half of 2026 or at all, might be more costly than expected or might not yield anticipated results, that FTD by the FDA may not actually lead to a faster development or regulatory review or approval process, that Q32 Bio may use its capital resources sooner than currently anticipated and such other risks and uncertainties identified in Q32 Bio's periodic, current and other filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequent filings with the SEC, which are available at the SEC's website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect Q32 Bio&#x2019;s results of operations and its cash flows, which would, in turn, have a significant and adverse impact on Q32 Bio&#x2019;s stock price. Q32 Bio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Q32 Bio disclaims any obligation to publicly update or revise any such statements to reflect any change in</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Contacts:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Investors: Brendan Burns</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Argot Partners<br>212.600.1902<br>Q32Bio@argotpartners.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Media: David Rosen</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Argot Partners</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">646.461.6387</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br>david.rosen@argotpartners.com</font></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:60.168%;box-sizing:content-box;"></td>
     <td style="width:1.76%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:16.157%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.76%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:16.157%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Q32 BIO INC.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(Unaudited)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">7,124</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">9,841</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">5,104</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">5,002</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">12,228</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">14,843</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(12,228</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(14,843</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of convertible notes</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">15,890</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Other income (expense), net</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1,197</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">158</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total other income (expense), net</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1,197</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">16,048</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Income (loss) before provision for income taxes and loss from equity method investment</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(11,031</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1,205</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Provision for income taxes</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Loss from equity method investment</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(176</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(11,031</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1,029</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) per share&#x2014;basic</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(0.90</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1.03</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net income (loss) per share&#x2014;diluted</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(0.90</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(6.33</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-average common shares&#x2014;basic</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">12,197,615</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">995,280</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-average common shares&#x2014;diluted</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">12,197,615</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2,334,180</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:65.727%;box-sizing:content-box;"></td>
     <td style="width:1.6%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:13.536999999999999%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.6%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:13.536999999999999%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Q32 BIO INC.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(in thousands)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(Unaudited)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">March 31,<br>2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">December 31,<br>2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Assets</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">65,483</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">77,965</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Equity investment</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2,526</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2,600</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Right-of-use asset, operating leases</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">5,571</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">5,722</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Restricted cash and restricted cash equivalents</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">647</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">647</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Other assets</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">4,844</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">5,398</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">79,071</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">92,332</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Liabilities and stockholders&#x2019; equity (deficit)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Accounts payable, accrued expenses and other current liabilities</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">7,977</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">10,468</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">CVR liability</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1,940</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2,900</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Lease liability, net of current portion</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">5,467</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">5,636</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Venture debt</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">12,701</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">12,653</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Other noncurrent liabilities</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">55,000</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">55,000</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Stockholders&#x2019; equity (deficit)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(4,014</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">5,675</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity (deficit)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">79,071</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">92,332</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img38152436_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img38152436_0.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0#X4&AO=&]S:&]P(#,N,  X0DE-! 0
M     -P< 5H  QLE1QP">  $3&]G;QP"6@ )0T%-0E))1$=%' )T  $ ' )E
M  $ ' )0  A(86YD+6]U=!P"7P "34$< AD  0 < FD "U$S,D))3RU,;V=O
M' (%  M1,S)"24\M3&]G;QP"-P *,C R,3HP-3HR-QP"<P '43,R($)I;QP"
M;@ '43,R($)I;QP"9P ! !P">@ "0TX< B@ #%-E92!296QE87-E(!P"%  D
M4%).07)C:&EV95\Q665A<GQ796)S:71E1&ES=')I8G5T:6]N' (/  -"24\
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M(UB8N7!#IAY+Y+M<J"V43ZVY5E/1TT8U?/42MCC:.USB % G-[;AQS>G2T>
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MO'+?7_PEBGXE/_N* *)J:DW+\QK6JW\BQ.V[<>3U0_<JK?BFCU/JY+?&]O\
MDD)^9;QA#:?R-Q%(R&GQ]0T4TAT$=RBDI#KXY&AOSJK1-3UK6^QTR[%5#8V\
M3IM1%+GK/<[==:)E9:ZZFK::3U,]-,V6-WB<TD+[ =0J;L$XMQ1@^Y"X85Q!
M<K-4 ZE]#4NBWO?-!T<.P@J3N1FV_B6U2PVW,VULO='P:;G;V-AJXQUNCX,D
M\FX?&HV>R31YQKI)S)""[Q/R>F'L3T1:SE;C_".8>&F7W!]\IKI1G0/,9TD@
M=IZB1A\)CNQP"V8*'<BM7!4S)5KD<F*; B(O#T(B( L%96'(",>*MMS+VPXG
MN5CJ<+8EDFME;-22/C9!NN=&\L);K)KIJTKSW;>.6^Z3Z4L4\!KZBG_W%"C.
MGUX\6_I^N\XD6L/^UN]Z?W*V,L]*K$547YE8==*E'JB+R+F<(7B#$&%+9?J6
M*2*"Z44-9$R33?8V1C7@.TX:@.&J]):KD7ZR>#_U>H/-XUM2JKD1'*B%E8N+
M44(B+$R"(B (B( B(@"(5^53404].^>>5D4432]\DC@UK&CF23P 0'ZK!*C;
MGEMDY=X.?/;L)M?BZZQZM)I).]T4;OQIR#OZ'H8'>,*(V<.TMFYF$Z6"MQ+)
M:+;+J/J=9B::/=ZG/![X_P KM.Q25/:JB;!5313U^Q'SW*"+)%Q7T+#<SLZL
MKLO]^/%.,[;25+-?YG'+W^I)ZN]1[SAY0%P3'VWAA*C?)#@_!MUNSAP;/<)F
M4<9/6&C?>1XP/(H($G>+M>+CJ3TD]JQJIF&R0,[:JY?D1,MXF=V$1"2.+MMK
M.&Z.<+1!8+''[7O%$:B0?M2N(/Q5SV^[16=]W<XU69E\B#O:T<C*8#^Z:U<P
M'%'.#1X3@T?C'1=[**F9L8AQNJZA^UZFRW',/'UP>7UV.,25#CQUDN\Y_P#D
MO/.)L2ZZ^F*\:_I&;Z2\V&*67[5$^37W#2[]R^GZD7;^JJ__  LG\%N1L:;$
M3D:M*1?%3TJ+&^,Z-P=28OQ! 6\C'=9QI_G6S67/G.:TD&BS-Q( WDV:M,[1
M^S('!:#44=7 XMGI9XB.8DB<W3X0OP#FDZ![2>H%8K#"[:U/D>I+*W8JD@<*
M;96=UH>ST;<[3>HV\"ROMK 2/?1%A76,#;>M.2R+&67\L?'PZBT5@>/[J4 _
MYU"@@CFL+FDMM+)M9APR-[+A4LV.^9:=EKM+Y,XV?'!;\8TMOK)> H[LTT<F
MO4"_P7'WKBNLPR,E8U\;FN8\:M<TZAPZP>E4L'B-#Q!Z"M[RGSDS*RWF9Z4L
M65U+3-.IH)G]_I7]AB?JT>-NA[5&3V)-L3O@I(PWE=DC?D6WHH@Y'[<=CN+H
M;;F=976>H<0TW2W!TU*3UOB.LD?DWQXE*O"F(+)B>QP7G#UVH[G;ZD:Q5-),
M)(W=FHZ>SF%"3TLT"X2-P]B7AJ8IDQ8N)Z:(BT&\(B( B(@"(B (B( B(@"(
M5@G0(#)X!:=G#F?@O+'#IO.,+U#11OU%/ /#J*IP]K%&/"<>WD.DA<=VM]JZ
MQY<.J<+8-%->\4LU9,[>WJ2VN_M"#X<@^Y@\/;$<C ''F+,1XUQ-48AQ5=ZF
MZ7*I/ASU#]2!T-:.3&CH:T #J4O0VE\^#Y,F\U(NLN;(>JS-WL=YVA]L+'6-
MWSVK!??,*61VK=^&0&OJ&_C2CA&#[EG'\8J-\LCY97RR/<^21Q<][CJYY/,D
MGB3VE?RBLT%-% W1C3 KLU1),N+UQ"(BWFD(B( B(@"(B (B( B(@"RQSFN#
MFD@M.K2#H0>L+"("0NSUM<YA9?N@M>(Y'XKL+-&]ZK)OYY3M_LYSJ7:>Y?J.
M@%JG7DAFY@?->PFY81O#)Y(V@U5#,!'54A/1)'S'OAJT]!51Z]/"&(;YA;$-
M-?<.76JMERI';T-532;CV]8[0>EIU!Z05$UEIAFZS.J[D2E+<Y(L&OS0N711
M:V2-KBTXUDIL*9BNIK/B%^D=-7C2.DN+N0!U^U2'W)\%QY$'1JE(#J%5YX)(
M'Z$B8*6*&>.9FDQ<C*(BTFX(B( B(@!Y%5:[>_LM\9?G$'F\2M*/(JK7;W]E
MOC+\X@\WB4U8_P#R'</JA$7GN6\3CZ(BM16@B(@"(B (B( B(@"(B (B( B(
M@"RWU0\:PLL]4/&@+2-@7V(F"OS2?SF5=A7'=@0Z[(F"_P UG\YE78E0JKOW
M\5]R[4_<LX($1%H-P1%I&>^:>%LI\#RXCQ/5;H.K*.CB(,]=+IJ(XV]?63P:
M.)63&.>Y&M3%5,7.1J:3ER/=Q]BS#V"L+U.(<47:FMEMI!K+43NT&O0UHYN<
M>AH!)Z H%[3FV#BG&DM18\OG5.&["=6.JP[=KZUO67#[2T^Y:=[K<.2Y+M#Y
MQ8OS@Q<;KB*I,-% X_4ZU0O/H>B:>H>V>1S>>)[!H!SU6BAM+(L'S9NW>"%<
MK+FZ3J19)S4_I[WO>Y[W.<Y[BYSB=2XGF2>D]J_E$4T1"J$1$ 1$0!$1 $1$
M !.NNJZ5L_9Y8]RBNK7X=N7HBU/?O5-GK'%U+-UD#G&[\9FG:#R7-46N2)DC
M=%Z8H9QR/C=I-7!2UO9NSSP=G'A\U%CG-)=J9@-?:*EP[_3?C#3U<>O)[>'7
MH>"Z>J:L%8DOF$<3T>(L.7*>W7.@D[Y3U$+M'-/2".3FD<"T\".!5E^Q_GU:
M<Y<(NCF9%08FML;?JG0-=X+AR$\6O$QD]'-IX'H)JMQMBT_7CS;[%EH;@D_4
M?D[W.S(B*))0(B( B(@"(B (B( B(@.-=T$]B!C/\A3>=PJKL\_*K1.Z">Q
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MA_VMWO3^Y;/G3Z\>+?T_7><2+6'_ &MWO3^Y?0(N[;P*._O%XEP.1?K)X/\
MU>H/-XUM2U7(OUD\'_J]0>;QK:E07]M2ZQ]A B(L3,(B( B(4 6"0.E?S*\1
ML+W$  :DDZ !0YVO]K^.W2U6#\I:J*>J83%68A: ^.$\BVF!X/</NAU:/:Z\
MQOIZ:2H?H1H:)ZB.!FD]3MVTCM"X%R@I'4URJ3<[\^/>I[+1O!F.O)TKN43.
MUW$] *@'M Y_YAYM54D-[N7H&R[^L5EH'%E,T='?.F5W:[AU +F=RK:RX5\U
M=7U4U555,ADGGGD+Y)7GFYSCQ)/65^*M=';(:=-)<W;_ +%:JKC+/DF3=QA.
M/4NA9&9*Y@YL7#O6%+.XT+'[M1=:HF*C@Z]7Z>$X>Y8''Q*:V1FQMESA!D-?
MB[>Q==6Z.(JV;E%&[\6 'PO'(7>(+.JN,%/DY<5W(8TU!-/FB8)O4@GEEEEC
M[,*J$.#<*W&ZMWMUT\46[3QG\:9VC!\*D5EML)8MKVQU&-\6V^SQN&KJ6W1&
MKF'87NW6 ^+>4[+=14E!114E%30TU/"T-BAAC#&1@= :. 'B7T*"GO50]<(^
MJGS)F&T0MS?F1ZP1L9Y*V0,=<K==,03-'A.N->X,)_)Q;@\AU74,,9/Y68>C
M#;/E[ANE(Y/%LB<_X[@7'X5NJ*.?4SR=MZK\3O93Q,[+40^:@M]#0L#*.CIZ
M=HY"&)K /@"^G1$6@W8(A^=33P5$1CGACE8>;7M#A\!6MX@RWR^OD;F7C!&'
MJX/YFHM<+S\.[JMH19(YS=BF*M:NU#AN,=DC(R_,=WK";[/,[^EM59)!I^P2
MYG^5<9S#V"WAKY\#8Z#CQW*6]4WS=^B_U8IKZ#5-%U17"JC[+U^.9S24-/)M
M;]"I_-;(/-C+QLE1B'"%6ZACYW"@_G5,!UES-2P>^ 7-ARU!U\2NH+01HN-9
MX;,65>8\<U7-9A8[Q+Q%SM#6PO<[KDCTW).W4:]H4M3WS'*9OQ3[$9/9_&)?
M@I5XMKRES*QKEI?_ *K8-OU1;I'.!GA!WZ>I'5+$?!?XR-1T$+H>T)LNYCY8
M-GN<5-Z8K!%JXW*W1.+H6]<T/%S/?#>;VA<1'+4<NA3;)(:EG55'(I$.9-3O
MSQ12QC9DVNL)Y@/I[!C)L&&<12:,C+Y/YE6NZHY'>H<?</\ (YRDB#JJ5NC0
M@'7K4F=DG:RON )*7#&/9*F]89&D<-429*NVMY#0GC+&/<GP@/4GVJ@JZS8)
MIP?+[$Q1W7'!DWS^Y8BB\W"M^M.),/TE\L5QIKA;JZ(2T]53R!\<C3T@_O',
M'@5Z05?7%,E)Q%QS0(B(>A$1 $1$ 1%_+SH@#G #50FVV]J^1\U9@'*NXED;
M2Z&YW^!W%QY.BI7#HY@RCM#?=+Y]OS:8DK*BMRPR\N);2,+H+Y=J=_&<\G4T
M+A[4<GO',ZM'#4F''0/W=2L-LM:*B33)P3ZJ0-PN.V*)>*_8RYQ<XN<223J2
M>E81%8R!"(B (L@$D =)T':5V[)+95S6S"CAKY;:S#=IE <VMO#71ND:>F.
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MU97=&Q>JG,(B*8(H(B]O+_"&)L;XEAL&%++576X3<1!3LUW&^[>X\&-'2YQ
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MF*]ZX(AS1QND>C&IFI^^RWD3B?.?$IBHM;?8:.0"Y7>2/>9%R/>XQ[>4CHY
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M5S<*4LO\SI'C0W>1IXZ_V#2-#[L\!P!6@[&^2]5G'F:RCJ6RQ8=M6[/>JEG
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MQ$62[E5>HVVFE /$NFX/^",2%5?'34Z<E9K%&J1O=O4KUY>BR-;N0PB(IXA
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M"(B (B( B(@"(B (B( B(@!5;_=.<)C#^TB^\PQM;!B:W15G@CAWYGV&3R^
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M&1QQMT:QH&@  Y #3@OU')4:HG=/*LCO$N4$+88T8WP"(BTFX(B( B(@"(B
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MB?K/YK_@TQ9\C3_13ZT&:_X-,6?(T_T5;LB:]E\B#4L?F4IZN.768%!&9*[
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MLVN^V/'NW#A[4#FNN9&93X-RGPHVRX4MHC=( :RNFT=4UKQ[:5^G'L:-&CH
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MJFU$1$P0(B*2/0B(@.&;?N&,Q<69%U%KP 6S-[[WV[T$0(J:ZF:->]Q'D?"
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M/9:Q_'?BUXQ./W2/4 ]8W7=*M4T6DY^Y98>S7R[JL)W^/<;)]DHZMC09:*<
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M59U<^'AR:[BYG[3>@*.JN,S*PC8L=8)N&%<248JK;<H3%,S71S3S:]I]JYI
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M]M/NIW \7#HC!UZ]T<Z[\5WR[XEQ'67Z_7">ON5?*9:FIG=JZ1Q_<!R '
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M@GP15T5]?N5VIMLT.:)BGH<+19<US7N:YI#F'1P(T+3U$="PI,CL B(@"(B
M(B( B(@"(B (L@'4#I)T':>I=IR.V7<T\QGPUAM)P]9I-";C=V.C+V]<</JW
M]AT:WM6J6>.)ND]<$-L4,DJX,3$XLUI<X  DN.@ YD]04F-F/9 Q7C>2FON/
MFU&&\/NT>VF<W=KZUO8TC["T^Z<-[J;TJ5&SYLRY<Y6.AN,-$Z^7^/0_5:XL
M#G1N_L8_4Q>,:N_&7:  %7JR].=BR#+U^Q.4MI1O6FS]#PLNL&X;P+A:GP[A
M6T4]LMM,/ AA;ZIQYO>X\7N/2YQ)*]X(B@E557%=I-(B(F"!$1>'H1$0!$1
M>;BNPVC$N'ZJQWZVTUQMU=&8ZBFJ(P]DC3T$'X0>8/$* VU?LC7[!,E3B7+J
M*IOF'1K)-0 &2MMXYG0#C-&.L>$!S!TWE86L%NO0%U4E9+3.Q9LW>!S5-+'4
M-P<F>\I6(165;2NRE@;,R6HO=G#<-8DEU>ZLI8@8*MW7/"- 2?=MT=U[R@OG
M?DKF)E57.;BJQ2"A+]V&ZTFLM'-U?9 / )]R\-/8K727&&H3!%P=N*U4T$T&
M>&*;SGJ)HB[SA"(B (B( B(@"(B (B_N&*669D,4;Y))7!D;&-+G/<>0 '$G
ML"8C _A==V4LA,29RXF#F-FM^&:.4"Y78LX<.)BAUX/E(\C==3T ]0V7-CF^
MXEEIL19HQ5%EL_"2.T-=N5M8.@2?<&'J]6?Q>:G9A>QVC#E@I;)8K=3V^WT4
M0BIZ6GC#(XVCH 'SGF3Q*@Z^[-8BLA7%=^XF:*V.>J/ER3=O/ER]PE8,$8/H
M<,X:MT5!;:"/<AA9\)<X\W.)U)<>))U7MH$57555<5VEB1$1,$"(B'H4!NZV
M@_7<PJ>CZA2><.4^5!KNNU$YN*,$7$-.[+15D!/1JU\3A_\ L5)6E?\ >-^/
ML1]S_P#%<0Z1$5R*F$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!#ZE$/J4";2W79
MN]CW@7]6;?YNQ;JM*V;O8]X%_5FW^;L6ZKY]+VW<2\1=VW@$1%@; B(@"(B
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M)&I_<3$N?#@>2SJJNL$;4^>.&F-BCQI)=(&_T5WIV56O[9 ?_F74<-[>F-(
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M%7NH;W;*VV5+3HZ"MIW0O'D> 5\6AZE<OB&R6:^T9I+W::&Y4_'[%64S)F?
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> &O:O3"(HQ55<U.]$1$P0(B(>A$1 $1$ 1$0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>qttb-20250508.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-08T07:03:18.4731+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.q32bio.com/20250508" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:qttb="http://www.q32bio.com/20250508" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="qttb-20250508.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  08,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Q32 Bio Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001661998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3468154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">830 Winter Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">999-0232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">QTTB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *\XJ%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( *\XJ%K7Q"^G[@   "L"   1
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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M;%!+ 0(4 Q0    ( *\XJ%K7Q"^G[@   "L"   1              "  <,
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *\XJ%J97)PC$ 8  )PG
M   3              "  > !  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ KSBH6IB'R/!O!   .1$  !@              ("!(0@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *\XJ%J?H!OPL0(  .(,
M   -              "  <8,  !X;"]S='EL97,N>&UL4$L! A0#%     @
MKSBH6I>*NQS     $P(   L              ( !H@\  %]R96QS+RYR96QS
M4$L! A0#%     @ KSBH6CJJHN=  0  / (   \              ( !BQ
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *\XJ%HD'INBK0   /@!   :
M              "  ?@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( *\XJ%IED'F2&0$  ,\#   3              "  =T2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "<4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="qttb-20250508.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="qttb-20250508.htm">qttb-20250508.htm</File>
    <File>qttb-20250508.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "qttb-20250508.htm": {
   "nsprefix": "qttb",
   "nsuri": "http://www.q32bio.com/20250508",
   "dts": {
    "inline": {
     "local": [
      "qttb-20250508.htm"
     ]
    },
    "schema": {
     "local": [
      "qttb-20250508.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_863635ad-1af5-4740-a2ab-f00b0d81a1e4",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "qttb-20250508.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_863635ad-1af5-4740-a2ab-f00b0d81a1e4",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "qttb-20250508.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.q32bio.com/20250508/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-25-066366-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-066366-xbrl.zip
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MR8/*QMPBE5OI[9:\+#L<WM !]-+':I2S,1W#M*C(GA3"G]B8&,&.]K\N$LS
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MW2$RP8T9V9G@Y 2]E^0C*\IZ.^*#MVJT[,T&N(7;L^\*I&L[M.=->5GT6S4
MNGT1?]$[KMEPJ/*ADIC3!W*!1"+-+Q#9\"/B( GH;R0!D0-:L"P(1@DS#DA8
MYJ20@U%:LDSDHR(=DP*849&,=<VZ0A[!U*M4J7J'M[K:>S2"=A1AV;CYEH!$
MRR^P'OK@)>:W%0_2MU<--C*-,E-G+.E5QC.0LK)#+4=SA1FI5K^[MMOLCCK.
M##V98K![X\6MNPX7PN"678=V%'F6B",J'!%2Q^8.#0UA4 LC-)9C>TGPX-3E
M/Y0L ;Z8TSC*ZL2ZXF9L)LKS-&* ("6@Z4,F^M./H>\XNXLDU?I@70T@ /,T
MA,APZDB%XQ%HGX[EUC1U[2@%/$%AV_1)]\,QL6RC!06O) 8>]_5 7/9>!BY;
MD6%&,:.>;R N!S9ED>%3CUG<,T OX\Z#]V&<@ ", >C9V2=@J,!5TPTB7R'R
M%73(H ;/32PV'49-:PJ19PX"F:"Q ]:#+OD*,9D[@0T,.0$C0R!6VIP&KA/1
M,+)MP%:3>P\/WWU6 CDRGM6H#W)"H:^.D@2/_=M@].18&V@]G@+30AYM.IQ:
MV]&;Y?"[*OL*,=SR/5?$;D@MS[8HH#M@J^\98% SY@A?@!*R:@SO%<5(J V>
MKPC/;4$=/$U[&3RORU[#\Y6?F!4^P8E9*Q265_J;FKAT9@ ].4=+,Y3:A@+@
M=EZ$<]*^S^;W^VS--]TGZLA9W-%C)7JN/")_W;UC3=P[ZY;A]#2N3;WYZQ2/
M3*\._8K[U=G(3Y@D<?N2D!\3_<^P-VE[&V1_.+*?*H:3KDYG'@^@]O:39E%M
M,'V#Z4_(U@_K8[$T5Q>-E@J*%?0&;ZZTKR?=N_$Z]VL(A]D\L"QJLQC,O2B(
M:.!Y-HWC) H"R^=VR![LI*LTZ[%I15JBWQ/CE@NT@)V48]-Y_&6'@.9,SEDZ
M$N1_8"T-PR1#O*"B_SH/S_D>&.J+(*K8=[CG1A9E2>SB=3,&#;F'.?\NCWD0
MV:;Y8,]WK3-4ZL)C4M2_3T]_V1#+AE@>BUBL*&'<"@P:&>B7,BR',M,)J..9
M1F0FMAOS!^_Z;210XQ+3F3HWW(VHBCQH(]IRRGY?D$-6</:5_)KF$4O))Z:^
MW&T+\+TR>1:>+G]':G@NWV@OX^@'%20:DUCG5<# OX#R*/3Y2->2'F1!8,@"
M@'F&<; SE5^4?72G#C$1@A6$BT1FU6&L5537<.><CG]U*+Y-MI&0_5W,8[;#
M71W@;>I ;X!A0SS-%7.**M>L%5%KR0/WK[>-WMJKZE.MM];)6SV3IO&X]U&L
M$R(>W()4"ZZ1P0'<$H:)N!6[INW1B'%4''R/!B&/*(^%'=G(U8)D-=F,S=A_
MU4/O5B-__@C,J\*?7O(-UK0##&DNGY,W\KKZP,5$*N(2N%B6ZU#%J!"Z%$R\
MSA[#NRWU57&DNN<.EUKWE8ZQ\PL)72/R9C 1^*+$N2R@7C*YC97%,1Z(BH7Q
M+D_.%"^JO#%^6YS$WF:3.,DTMVLM0R)WPZ?'. !ZUGDS_P:]-4ZQ_/;EA$DJ
M+BF7JEHKC!^-!MEN<_\G?KUY?^%_1D4IDW'3JRY% ;\67&S8G[AI:@A7=ZY2
M?5=C%0&;_0!-5J^'[$Q47ALPI4#L=5AZP<9%'=Y9KUL7E[I ;=%M6H^6T/KH
MX=->*0;$:AD6WLT\2DN]2_@(>$T=L0:.,76U<S<'YH8?KNX2F+G[:SK1PFMY
MGK^ZZ[_65!@<900O9*GO8]DAT_<M / RX+TQ:JD V"N>K&I0(R]')OMUI&\2
M(!7/![LB[A/;K)K4*S#AUXPT)X8*,AKBC30ML@_OAI/DX*'>Z@T8+A@($XGI
MD%E6<W8M+70V<STPG:, ZFDD4#XD(YAPT<=N4,WMRTB6) Q;)DH'K<9V1TIA
ME?IV'SQ7LTY];CTJ2U_3Q9^O0+\^(D#;6%[MLT&L6X N9%M.]HS.8!HK2Q8C
M"H)-*,K\S?5<^DA,HRF01M$'/5?K3_")"T!I3M ,LP"R,A5<_S9W-:V!M@,R
M0&@>-]%V@B5MO!VD"C:H1K*-%>INI@O7O6DK,D>[]@+4,5*,HO] =Q49"9)*
MIM,_9#62LL]*4E3#V8&9J'I.<GI*<G)4,#R 9CFY(1J!C0I@O9/@UL3FV@J>
MGL4.R6^F'.U@:$<,]94GXE)S$]RS($J$(+ /Z+NH;D*)9P=1C(!K5:-X5F:P
M]K>Q?N?*1-@RS"F501\FA7*FTB5J8B]F%(CUS;YR6X8;WB<O"C2J>U0+[59H
M/>W%):N)I0XDYZE8PIE=-?<,08"5.H-15#U&0."5@9&0UP-$1OH*/7]?RS*B
MXC(,_S);_7)P.WB39#YX==M<Q/6U 1TM\='^KA-4[I2M#*;"<6,J8&*WUBUF
M;)A\QL"9K!>[0WJ'M^%(CT]*CWWF[ :>"[#<UEM(-GC^N.MB&L[KD1D;P;O.
M0.SF,'_RF8'=W,-\"1;KXQ3?LY)5U\ULBT$D.+H+T/&FG2)85,OJ/W\Y_DAX
M?>GTYJ"[31CDF<,@*T:M^A"0%[2-K/?KX?[I[\<')X_HN[H)E77RXGZ>B@57
MH>JO(Z"PRG>SK(]T3HR;C](QB=D(X]+:+:PJ=W#ES2T #/ !O<8E!B+Z+$W0
M",&&M&E3%T!_\"B#.KHYH*]^K@  ?-K7N+Y^).\^^^2<>U3R[].1_0(]3IN$
MTPW0-D![^4"[7VJST[+O%$6IRC_S+BKM5^L=D=YAM[6\>V'#6;\K?-\ ;0.T
M#=#6YNJOM5F'NTJTI_5UO0<;J/,"L'F]H3@OD+:!Y?U@^<OX":\86+<C![Z'
M!6P7;?*OG$M!/N5*R2+/7B?C?R$"> .T#= >C1?@QM[.2\@@7RX=&D_+> G:
MDM'R[W8RX$KC%TO!\IJ$P'-HNGTIDAOWUZE-#/75Q5#WVE'.Q^]^V&OWRT'Z
M[O\!4$L#!!0    ( *\XJ%I]].,:J @  +YA   1    <71T8BTR,#(U,#4P
M."YX<V3M7']OVC@8_O\^A2_[9],M),!Z:U'IQ+7K"5W75J7337<Z32$Q8"W8
MS$E:^/9G)W%^X00*30*(:5I9\OIYGR?^$?NIS?FG^=0&3Y ZB."NTFSH"H#8
M)!;"XZ[R=:#V!I?]OO+IXI?S7U457%WW;\$M? 8]TT5/\ HYIDT<CT+P=O#E
M'?CVQ\,-&)@3.#7 %3&]*<0N4,'$=6<=37M^?FY8(X0=8GLN2^<T3#+5@*J&
MX)<4&OPZN#)<"#HMO76BZNSOZ:/^L:.W.\W3QH>/[>9ONM[1]40Q,EM0-)ZX
MX*WY#O!2+#?&T+;A EPC;& 3&388B*SO01^;#="S;?# BSG@ 3J0/D&K$8#.
M':OC!")<@XZA>VM,H3,S3-A5$E)^MEM#1'P-/*E^HI\JP'!=BH:>"Z\)G5[!
MD>'9;E?Q\$_/L-$(08L]7AORYY(*2-QF]8&=#L3>M!6EFP^IW2!TS!/I&IR[
M$#MH:$.5AT'J/S5';?'*"XK_=-WA:K)!+).;"GUNAZGTIO;MRTU0G2+81OA'
M*CI!36]K_/;0<* (]QQU;!BSJ,3(<(9^='B#D_D@@BV(THH=:#;&Y$EC-U*!
M_*;ERIZ.?J(%-Y.AJ( P:XTN:R 1X?F2P/!Q-,_.SC3_KG+Q"P!^(T'3&:$N
M"-K*#3']>BA(QO^GBHPJOZ0V6VJ[V6!@"L#25I9#5]N.A*BGC4A$E;PI"5%)
M//M)7EYIK:Z5T<EK/_R#RC\4YEQJ=2]+*FWB&K1=1UPII"#O(3$% V/B^GGY
M)7%Q-D-X1((K[!JOH0XE-GQ<S"#@'[X^]%>-!YIKS DFTX7&"VAB_!8_>]CZ
MC%WD+OHL$YWZ%!2 V-CQP,*_KQ4N" J*%F2O ^2+:>K\#WM9)-X;T4<&!@(T
MD( [U[(@&7C/@=8=OO _SR@;Y''PY&[8A;!P&%)0T#1LT[-?7BZFE5LLO"@J
M*EU]HI?YC]@.AYUL_3[ 4:G5ZP]XG0F%(_:.8N\45:#QYOMF_8H/@5RFLJLX
MK!O9X>B14FP,H<T?5AC->18,0[X,?T 6Z,CE!2*8=%;_K6FQ-VR<-DI,S%2H
MS7LVH6GYZX\L;]A_OE\2-JGJ#1V7&J8KD'QJ767YOE8-J1ZK(,N??-C&6$(J
M?;\B4I>LK?38U.^26%#VH)*W*Z(DVO(]I(BPYFSQ&:F$FSRN8I)\Z"C@YM^N
MB%+0\7N6Q09;)_S!>B)L2OCEQ]9!EK>R._I(GO$JJHG(.HC>$S8#M/]!LYSN
M4A!<!]T!>^/".WI/R1,*IMF%A+/AE5*^9+V%&G:?O27F?\%%+M=L7*4D/[/U
MWI@MSO^DY-F=7)+IS,#Y5.71E1*^1C:\]:9#2'-9)D(JI=;')J%L1N_/4?RF
M=TD\5K>+PKY57*IB =$4B]L)D-[ L6'?T0<X1HX+*;2X=5&@9*WBE4H*<E,#
MNX74,V&54GPTYGV+C0%HA((5X(KFG1=?$6F^3K7O)P3G=\.ED(JHW5/6=Z9L
MEF+ZEEC?<3Q('_DTG=Z-1E*J*XO40_U%I&N@.X"F1UE;;+:&CWR9)"&Y%%(Q
MM<]S<V+@,<SI]]*PJB@2&YEL+8_'7]AP3Y%ARP@N!U5$[Y$:W*\?+*9#(F.6
MOE\1J;]99;$5-V_W'@X'/D="3AXG(\G+<)N6?>*_G(!8_3I(K_'9%))X5#K-
M3*VWO]O#Z#FMY3)P'.7"QP#_"I3_0O_&O_O:?%-+\0WY1AB @Y3)-KE(W_3A
M<G>/8P .4B99Z:I]0]:111F  8;F__JJ"OY\9;\M;8Y1)M?<5?Z&Q$,7.$1Z
M+SX C@GN<'5:8AO@E93X[9]0P"$K4Y$R"%Y)2( )&&CI/;G(.W@E-3XJKQ>!
M6[Z>C+^PG9 0#/AH@,&5SU]J.FRG0D"" !.$H.5KB:V)[01P'!  E4^ZT*'8
M3D<*.M$[P@05]?CUC(MME48YWH,@"_#3<+EQ(L SE:\X[7=LIRS&JHA\C@&R
MG0H&"M*H%?2OK%&RH00?!O@X%9!>99EL*(+!JF8"%P3 ($ &/G2%LDH05)62
MK/.R(7^_+" CT&R]';X# K4*YDE39D/V @H(K-('IV7#9E/J$1 02&7R3MDY
MF[:5  ,$(&6RE?H[&[(.L4 :; WV/9HVN QJBO3LXPH&881F$C8PS%PU(!,6
M'U$RE>WH$.E(GOV4YW!5056Z#T1077:>ZJ0JVQT2/=2LZU0GT<(](X)QOO6T
M"]23.TFRC".SJ4ZB*_>7"-;%MM/.2%C>=2(5D/&:=H:^="^*5,&RS[0S(G)V
MJ$AER"RF^H7D[%M)*Y"92O53+]S-DA:0[RK5+V-YCTN:>\9%JI_P6CM?TAI6
MFTJ[(.LE^V&R^M;VE.H7*M\EDQ8DL8SJ)[YB[TQ:09%O5*>4O!TU@KW4):J3
M\+K[;(2 M1RC'1*TOI1=$I&W)T=0E]I"NT!8ME,G2WK)$:J5>.[^G8BVW NJ
MD[1T5X_@N^P!U4FU<*^/H)QO!"5/ B6\'+9@^Y$](Y0]QI7G(;WN :CP9%$V
M>=H#.QXP.AXP.AXP*I?2\8#1\8#1\8!1J22/!XR.!XR.!XR.!XR.!XR.!XR.
M!XR.!XQRK8B\'2E[>\ HN;Q_%==D9E"&IYH39%LOW"^264@3ROIS5VGJ>E/G
MW_(U8\M!WE:[2DL!GL/(D!FG+6\2NR0LO1B/=#7;>ZXK9T4?5USK0 0&;D"L
M2]]S70660BSR[)!$)JV(N ,>5#UF3(Q8Y;[WPF+O(]:Y[Z^)',,D[I$?#D)@
MCMD2RSPY")E)BR;6]OM!:%OA\<1R/QZ(W/4<H7@H.HPFG+6-XGK=]YGK"L\I
M%GJZYT*7?:JXD>[[ZV2UT15KW??);)$S%JO<]]:Z;*A%VEK[/KN3.W*1OO:^
M]T:9G1>WS'V?"&3<P+A9[OOB*L=1C&ON)3/6<"=3=L]0YKN?^3_\6YZ#R^=:
MYMN\PPN)[_P.K@3?0'[Q/U!+ P04    " "O.*A:Q=P\%_<C   7A ( #P
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M9W6'7[-^W"U>-V4[U'BPK:=.L=.[7B]Y'RN\UW0QXMS?[55[%L4[(NYE_7]
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M!D,X-K1],;27[]^=7[R[O#@7\-OE^S>OS_M7\,>+_IO^NY<7XO+7BXNK2[9
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;,2YH=&U02P4&      ,  P"[    @4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>qttb-20250508_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="qttb-20250508.xsd" xlink:type="simple"/>
    <context id="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
        </entity>
        <period>
            <startDate>2025-05-08</startDate>
            <endDate>2025-05-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_92c8ec95-21b0-4e9f-9462-38a1337cbf50">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_0398cdf9-7f98-495b-8b83-4adf1550d5fa">0001661998</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_684fbbcf-7770-401e-bd5f-f47e969627f3">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_e9f10ee6-5616-4c1c-ba34-c73c4923b7db">2025-05-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_42ee7a28-cb72-430a-84e6-f485a38aee62">Q32 Bio Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_63fa0557-962d-47a7-ac7e-d774dc7ddf33">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_f918bfd0-8853-43f1-95a2-0887a9078987">001-38433</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_78822aaa-02b7-433f-bd80-a116e3ea6095">47-3468154</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_bbb2cd4c-5bd9-46e4-a0e7-50bc4fddd119">830 Winter Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_b157d42a-60b4-4a63-9ede-ef87e0ea5f2d">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_ba640e0c-935d-4c6a-891f-49108eb93144">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_aafc79f2-7bc2-42d2-bf78-d3c426ae2c8b">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_73615c3f-9473-41fd-81c8-1dc66481fc48">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_c2d82a18-11a5-4af0-92e7-7b0015a084ab">999-0232</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_acbe1bb1-28f3-41f7-bdab-d717c9c15826">N/A</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_3bb62ecb-e4e9-43d4-90e0-2108e2436f85">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_32b01bca-6709-4383-ab07-6a2d60826d47">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_d483e4ef-28e5-473d-854b-9b3335a1d68b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_2765ec59-2632-4830-a760-41aa4e7e90eb">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_e4a3d822-3ac0-4b8b-8663-ccfb8827d39a">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_c74d65b2-afc5-4950-9d62-bf5dcd8b3117">QTTB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_2bfad280-b03e-4024-a148-4610b1f35cd9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_863635ad-1af5-4740-a2ab-f00b0d81a1e4"
      id="F_bd2c5136-bad5-4976-89db-dce3b3a1e48f">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
